NCT00563290View on ClinicalTrials.gov

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

October 31, 2014

Conditions
Recurrent Skin CancerSquamous Cell Carcinoma of the SkinStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic Leukemia
Interventions
DRUG

dasatinib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (3)

43210

Ohio State University Medical Center, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00563290 - Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter